Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice
Ruxolitinib is the first janus kinase 1 (JAK1) and JAK2 inhibitor that was approved by the United States Food and Drug Administration (FDA) agency for the treatment of myeloproliferative neoplasms. The drug targets the JAK/STAT signalling pathway, which is critical in regulating the gliogenesis proc...
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Research
2021
|
Series: | Scientific Reports
|
Online Access: | View Fulltext in Publisher View in Scopus |
Search Result 1
by Abdullah, MA, Abidin, SZ, Cheah, PS, Habib, O, Hamzah, H, Hassan, Z, Lee, HC, Leong, MPY, Lim, SM, Ling, KH, Moklas, MAM, Nordin, N, Seth, EA, Vidyadaran, S, Yusof, HM
Published 2021
View Fulltext in PublisherPublished 2021
Article